Table 2. Characteristics of the Validation and Derivation[5] cohorts.
| Validation Cohort (Lille) | Derivation Cohort (Sainte-Anne) n = 228 | p-value | |
| n = 230 | |||
| Baseline characteristics | |||
| Male gender | 104 (45) | 122 (54) | 0.08 |
| Age, mean ±SD, years | 70.4±16.0 | 67.3±14.9 | 0.03 |
| Hypertension | 156 (68) | 124 (54) | 0.003 |
| Diabetes mellitus | 38 (16) | 30 (13) | 0.31 |
| Current smoking | 43 (19) | 42 (18) | 0.94 |
| Atrial fibrillation | 48 (21) | 63 (28) | 0.09 |
| Previous stroke | 20 (9) | 20 (9) | 0.98 |
| Prestroke mRS >1 | 23 (10) | 6 (3) | 0.001 |
| Before IV-tPA | |||
| NIHSS, median (IQR) | 8 (5–14) | 14 (8–19) | <0.0001 |
| OTT, median (IQR), min | 149 (120–191) | 160 (125–195) | 0.26 |
| Serum glucose, mean ±SD, mmol/L | 7.3±2.7 | 6.7±2.2 | 0.01 |
| Systolic BP, mean ±SD, mmHg | 156.3±20.2 | 152.8±22.9 | 0.08 |
| Diastolic BP, mean ±SD, mmHg | 82.5±14.1 | 82.9±15.6 | 0.94 |
| M1 occlusion | 75 (33) | 135 (59) | <0.0001 |
| DWI-ASPECTS, median (IQR) | 8 (7–9) | 7 (6–8) | <0.0001 |
| DWI-ASPECTS ≤5 | 33 (14) | 46 (20) | 0.10 |
| Outcome | |||
| 3-month mRS >2 | 78 (34) | 98 (43) | 0.05 |
| 3-month mRS >4 | 23 (10) | 42 (18) | 0.01 |
Numbers in parentheses are percentages, unless indicated. SD: standard deviation; IQR: interquartile range; IV-tPA: intravenous thrombolysis; OTT: Onset-to-treatment time; M1: M1 segment of the middle cerebral artery; mRS: Modified Rankin scale. NIHSS: National Institute of Health Stroke Scale. DWI-ASPECTS: Diffusion-weighted imaging Alberta Stroke Programme Early CT score.